USA flag logo/image

An Official Website of the United States Government

NON-PROTEIN MR CONTRAST AGENT FOR BREAST CANCER IMAGING

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
16430
Program Year/Program:
1991 / SBIR
Agency Tracking Number:
16430
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Biointerface Technologies, Inc
1202 Ann Street Madison, WI 53713
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1991
Title: NON-PROTEIN MR CONTRAST AGENT FOR BREAST CANCER IMAGING
Agency: HHS
Contract: N/A
Award Amount: $49,492.00
 

Abstract:

BREAST CANCER IS THE MOST COMMON MALIGNANCY IN WOMEN. FOR CANCER DIAGNOSIS, THE SEARCH FOR CONCEALED METASTASES IS THE SINGLE MOST IMPORTANT FACTOR IN THE TREATMENT DECISION FOR ALL CANCER PATIENTS. EVEN THOUGH CURRENT METHODS SUCH AS NMR HAVE IMPROVED THE DETECTION OF METASTASIS, THE MAJORITY OF METASTASES ARE RARELY DETECTED EARLY. CONTRAST AGENTS ARE BEING DEVELOPED TO SELECTIVELY HIGHLIGHT CANCEROUS TISSUE AS COMPARED WITH NORMAL TISSUE. THE MOST ACTIVE APPROACH IS WITH THE USE OF ANTIBODY-BASED CONTRAST AGENTS. THESE AGENTS ARE COSTLY AND HAVE LIMITATIONS SECONDARY TO IMMUNOGENICITY, PURITY AND MANUFACTURABILITY. WE WILL DEVELOP A NON-PROTEIN BASED CONTRAST AGENT FOR USE IN MR IMAGING WHICH WOULD SELECTIVELY HIGHLIGHT PRIMARY AND METASTATIC BREAST CANCER TUMORS. THIS NEW TUMOR SPECIFIC TECHNOLOGY WOULD BE SUPERIOR TO OTHER APPROACHES IN THAT THE AGENT IS NON-IMMUNOGENIC, PURE, EASILY MANUFACTURED, AND LOW COST. THE AIM OF PHASE I IS TO SYNTHESIZE, PURIFY, CHARACTERIZE AND PERFORM MR IMAGING STUDIES WITH A MODEL MR CONTRAST AGENT THAT IS SPECIFIC FOR BREAST CANCER. IN PHASE II, WE WILL MAKE ANALOGS OF THIS COMPOUND, EVALUATING THESE ANALOGS USING IN VITRO AND IN VIVO MODELS, AND PERFORMING PRE-CLINICAL STUDIES ON THE OPTIMAL COMPOUND. CLINICAL EVALUATION OF THE OPTIMAL COMPOUND IS SCHEDULED FOR SBIR PHASE III.

Principal Investigator:

Capelli, Christopher C
Principal Investigator
6082564300

Business Contact:

1 r43 ca55422-01
Small Business Information at Submission:

Biointerface Technologies, Inc
1202 Ann Street Madison, WI 53713

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No